PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: Inhibitors that directly target PARP have been found to block the SSB repair pathway, triggering homologous recombination deficiency (HRD) cancers to form synthetic lethal concepts that represent an anticancer strategy.